Radius Health, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$36.4M
Doctors Paid
27,481
Transactions
138,349
2024 Total
$1.0M
Payment Breakdown by Category
Research$20.8M (57.2%)
Consulting$4.9M (13.6%)
Food & Beverage$2.8M (7.7%)
Royalty/License$1.7M (4.7%)
Travel$986,070 (2.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $20.8M | 5,574 | 57.2% |
| Consulting Fee | $4.9M | 469 | 13.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4.4M | 2,162 | 12.1% |
| Food and Beverage | $2.8M | 124,168 | 7.7% |
| Royalty or License | $1.7M | 10 | 4.7% |
| Travel and Lodging | $986,070 | 3,403 | 2.7% |
| Current or prospective ownership or investment interest | $232,906 | 2 | 0.6% |
| Honoraria | $208,278 | 136 | 0.6% |
| Education | $147,010 | 2,364 | 0.4% |
| Grant | $85,602 | 14 | 0.2% |
| Space rental or facility fees (teaching hospital only) | $57,200 | 39 | 0.2% |
| Charitable Contribution | $2,716 | 8 | 0.0% |
Payments by Type
Research
$20.8M
5,574 transactions
General
$15.6M
132,775 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF ELACESTRANT (RAD1901) VERSUS INVESTIGATORS CHOICE OF FULVESTRANT OR AROMATASE INHIBITOR THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER+/HER2- BREAST CANCER | $5.7M | 0 | 696 |
| A Randomized, Double-blind, Placebo-controlled, Phase 3 Multicenter Study to Evaluate the Safety and Efficacy of Abaloparatide-SC for the Treatment of Men With Osteoporosis | $3.0M | 0 | 747 |
| A Randomized, Non-inferiority, Phase 3, Open-label, Multicenter Study To Evaluate The Efficacy And Safety Of Abaloparatide-smts For The Treatment Of Postmenopausal Women With Osteoporosis | $2.2M | 0 | 474 |
| Abaloparatide-TD, Phase 1, Pilot PK, Healthy Postmenopausal Women | $998,701 | 0 | 11 |
| A Phase 1, First-in-Human, Multi-Part Study of RAD140 in Postmenopausal Women With Hormone Receptor Positive Breast Cancer | $873,554 | 0 | 221 |
| A Randomized, Multicenter, Phase 2 Study Of Elacestrant (rad1901) Versus Investigators Choice Of Fulvestrant Or Aromatase Inhibitor Therapy For The Treatment Of Postmenopausal Women With Er+/her2- Breast Cancer | $849,752 | 0 | 75 |
| A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer | $763,542 | 0 | 332 |
| A Phase 3 Extension Study of RAD011 (Cannabidiol Oral Solution) in Patients With Prader-Willi Syndrome | $697,656 | 0 | 53 |
| An Open-label, Single-arm, Multicenter Study to Evaluate the Early Effects of Abaloparatide on Tissue-based Indices of Bone Formation and Resorption | $524,352 | 0 | 98 |
| A RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF ELACESTRANT RAD1901 VERSUS INVESTIGATOR'S CHOICE OF FULVESTRANT OR AROMATASE INHIBITOR THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ERHER2- BREAST CANCER | $520,722 | 0 | 67 |
| A RANDOMIZED, NON-INFERIORITY, PHASE 3, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABALOPARATIDE-SMTS FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS | $445,874 | 0 | 1,613 |
| Dissecting differences between abaloparatide and teriparatide signaling in bone cells | $338,748 | 0 | 11 |
| A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Phase 2, Multi-Center, Dose-Finding Study to Evaluate the Effects of RAD1901 in the Treatment of Vasomotor Symptoms in Postmenopausal Women | $271,045 | 0 | 7 |
| Abalo Added to Ongoing Denosumab vs Continued Denosumab Alone | $255,437 | 0 | 3 |
| Mechanisms of action and pre-clinical activity of ER antagonist/degrader RAD1901 | $224,000 | 0 | 1 |
| Phase II Trial of Abaloparatide vs Placebo - Spinal Fusion - Phase II Trial of Abaloparatide vs Placebo in Post-Menopausal Women Receiving Initial Spinal Fusion Surgery | $210,265 | 0 | 3 |
| Dissecting Differences between Abaloparatide and Teriparatide Signaling Bone Cells | $190,520 | 0 | 10 |
| Phase II Trial of Abaloparatide vs. Placebo in Post-Menopausal Women and Men Receiving Initial Spinal Fusion Surgery | $189,448 | 0 | 2 |
| G Stimulatory Protein-Mediated Signaling Downstream of PTH1R | $188,400 | 0 | 3 |
| Pre-clinical development of small molecule SIK2/3 inhibitors for osteoporosis related musculoskeletal indications | $176,884 | 0 | 1 |
| Differential effects of parathyroid hormone analogs on skeletal stem cells | $174,916 | 0 | 6 |
| RAD1901-308 | $142,812 | 0 | 142 |
| Draft Results with data sufficient for abstract submission | $135,000 | 0 | 3 |
| Untitled | $124,691 | 0 | 5 |
| Male Sub-Analysis of the Medicare Cost of Illness Study | $108,000 | 0 | 2 |
| A PHASE I, MULTICENTER, OPEN-LABEL, MULTI-PART, DOSE-ESCALATION STUDY OF RAD1901 IN POSTMENOPAUSAL WOMEN WITH ADVANCED ESTROGEN RECEPTOR POSITIVE AND HER2-NEGATIVE BREAST CANCER | $106,440 | 0 | 28 |
| A RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF ELACESTRANT RAD1901 VERSUS INVESTIGATORS CHOICE OF FULVESTRANT OR AROMATASE INHIBITOR THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ERHER2- BREAST CANCER | $96,068 | 0 | 14 |
| Mechanisms of action and pre-clinical activity of ER antagonistdegrader RAD1901 | $96,000 | 0 | 1 |
| A Phase I, Multicenter, Open-label, Multi-part, Dose-escalation Study Of Rad1901 In Postmenopausal Women With Advanced Estrogen Receptor Positive And Her2-negative Breast Cancer | $92,630 | 0 | 9 |
| Phase II Trial of Abaloparatide vs Placebo - Spinal Fusion | $90,114 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors — Page 4
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Aaron Broadwell, Md, MD | Rheumatology | Shreveport, LA | $22,087 | $0 |
| Dr. Daniel Bikle, Md, MD | Endocrinology, Diabetes & Metabolism | San Francisco, CA | $22,057 | $0 |
| Paul Miller, Md, MD | Nephrology | Lakewood, CO | $21,566 | $0 |
| Ruban Dhaliwal, Md, MD | Endocrinology, Diabetes & Metabolism | Dallas, TX | $21,421 | $0 |
| Dr. Irinel Stanciu, Md, MD | Endocrinology, Diabetes & Metabolism | Arvada, CO | $20,812 | $0 |
| Dr. Heather Hofflich, Do, DO | Endocrinology, Diabetes & Metabolism | La Jolla, CA | $18,760 | $0 |
| Eric Orwoll, Md, MD | Endocrinology, Diabetes & Metabolism | Portland, OR | $18,139 | $0 |
| Anne Lake, Dnp, Aprn, Fnp-C, DNP, APRN, FNP-C | Nurse Practitioner | Archdale, NC | $17,865 | $0 |
| Unknown Provider | — | — | $17,645 | $0 |
| Dr. John Potts, Md, MD | Internal Medicine | Boston, MA | $16,508 | $0 |
| Unknown Provider | — | — | $15,848 | $0 |
| Neil Sheth, Md, MD | Orthopaedic Surgery | Philadelphia, PA | $15,136 | $0 |
| Kenneth Saag | Rheumatology | Birmingham, AL | $14,913 | $0 |
| Dr. Shaun Hussain, Md, Ms, MD, MS | Neurology | Los Angeles, CA | $14,575 | $0 |
| Dr. Kevin Kirk, Do, DO | Orthopaedic Surgery | San Antonio, TX | $13,937 | $0 |
| Annette Gantz, Fnp, FNP | Family | San Antonio, TX | $13,627 | $0 |
| Natalie Cusano, M.d, M.D | Internal Medicine | New York, NY | $12,715 | $0 |
| Dr. Gregory Emkey, M.d, M.D | Rheumatology | Wyomissing, PA | $12,672 | $0 |
| Kyle Mitsunaga, Md, MD | Orthopaedic Surgery | Honolulu, HI | $11,475 | $0 |
| Dr. Thomas Olenginski, M.d, M.D | Rheumatology | Danville, PA | $11,428 | $0 |
| Mr. Michael Mcclung, M.d, M.D | Endocrinology, Diabetes & Metabolism | Portland, OR | $10,967 | $0 |
| Risa Kagan, M.d,, M.D, | Obstetrics & Gynecology | Berkeley, CA | $10,684 | $0 |
| Michael Econs, Md, MD | Internal Medicine | Indianapolis, IN | $10,345 | $0 |
| Dr. Robert Adler, M.d, M.D | Endocrinology, Diabetes & Metabolism | Richmond, VA | $10,197 | $0 |
| Dr. Richard Fausel, Do, DO | Adult Medicine | Rancho Mirage, CA | $10,043 | $0 |
Ad
Top Products
- Tymlos $11.7M
- Elacestrant $26,142
Associated Products (3)
- Tymlos $11.7M
- Elacestrant $26,142
- Elacestrant Orserdu-345 mg $14,945
Payment Categories
- Food & Beverage $2.8M
- Consulting $4.9M
- Travel & Lodging $986,070
- Research $20.8M
- Royalties $1.7M
About Radius Health, Inc.
Radius Health, Inc. has made $36.4M in payments to 27,481 healthcare providers, recorded across 138,349 transactions in the CMS Open Payments database. In 2024, the company paid $1.0M. The top product by payment volume is Tymlos ($11.7M).
Payments were distributed across 195 medical specialties. The top specialty by payment amount is Internal Medicine ($3.4M to 5,328 doctors).
Payment categories include: Food & Beverage ($2.8M), Consulting ($4.9M), Research ($20.8M), Travel & Lodging ($986,070), Royalties ($1.7M).
Radius Health, Inc. is associated with 3 products in the CMS Open Payments database.